This is BrainsWay’s global website. The website includes information on clinical indications that were not cleared by the FDA and are considered investigational by the U.S. medical device regulations. BrainsWay treatment is FDA cleared for patients with MDD who failed to respond to one or more anti-depressants in the current episode.
Yossi Ben Shalom was appointed as a Director at BrainsWay on December 2018.
Mr. Ben Shalom is a co-founder of D.B.S.I, a private investment company specializing in investments in mature companies that are positioned globally for high growth or built for vast expansion through M&As.
As such, Mr. Ben Shalom serves as the Chairman of Pointer Telocation Ltd. (Nasdaq:PNTR), Rada (Nasdaq: RADA) and Shagrir Group Car Services Ltd. (TASE: SHGR), The 8 Note Production & Distribution Ltd., Car 2 Go Ltd., Matzman Et Merutz Milenum
He also serves as a director at Taldor Computer Systems (1986) Ltd. (TASE: TALD), Eldan Cargo Ltd., Ltd.
Mr. Ben Shalom was formerly Vice President of Koor Holdings (NASDAQ:KOR), and served as the CFO of Tadiran Ltd. Mr. Ben Shalom was an active director in numerous boards, such as NICE Systems, Machteshim Agan, Bank Klali, M-systems, and others.
Mr. Ben Shalom holds a BA in Economics and an MA in Business Administration both from Tel Aviv University.